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Abstract
Cutaneous malignant melanoma is the most fatal skin cancer and although improved comprehension of its pathogenic
pathways allowed to realize some effective molecular targeted therapies, novel targets and drugs are still needed. Aiming to
add genetic information potentially useful for novel targets discovery, we performed an extensive genomic characterization
by whole-exome sequencing and SNP array profiling of six cutaneous melanoma cell lines derived from metastatic patients.
We obtained a total of 3,325 novel coding single nucleotide variants, including 2,172 non-synonymous variants. We
catalogued the coding mutations according to Sanger COSMIC database and to a manually curated list including genes
involved in melanoma pathways identified by mining recent literature. Besides confirming the presence of known
melanoma driver mutations (BRAFV600E, NRASQ61R), we identified novel mutated genes involved in signalling pathways
crucial for melanoma pathogenesis and already addressed by current targeted therapies (such as MAPK and glutamate
pathways). We also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which
might deserve further investigations. All data are available to the entire research community in our Melanoma Exome
Database (at https://155.253.6.64/MExDB/). In summary, these cell lines are valuable biological tools to improve the genetic
comprehension of this complex cancer disease and to study functional relevance of individual mutational events, and these
findings could provide insights potentially useful for identification of novel therapeutic targets for cutaneous malignant
melanoma.
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Introduction
Cutaneous malignant melanoma is the most fatal form of skin
cancer and its worldwide incidence has doubled in the past 20
years. While at early stages it can be surgically treated, metastatic
melanoma has a very poor prognosis; furthermore, it is largely
refractory to existing therapies and the standard first-line
chemotherapy (dacarbazine and high-dose IL-2) has a dramati-
cally low response rate, with severe toxicities [1]. So, melanoma
has become an increasingly important public health issue and new
therapeutic strategies are urgently needed.
Research studies conducted over the last decade on melanoma
molecular pathogenesis improved the elucidation of its key
signaling pathways, such as those mediated by Ras/Raf/MEK/
ERK (alias MAPK), PI3K/Akt/mTOR, Wnt/b-catenin/APC,
MITF and glutamate cascade [2]. The understanding of their
broad functional interplays and genetic alteration patterns helped
to unravel the complexity and heterogeneity of melanoma and in
the meantime provided targets for development of new mutation-
driven therapeutic approaches (known as targeted therapy). The
best example is represented by the selective BRAF inhibitor
vemurafenib, the first FDA-approved targeted drug successfully
used on BRAFV600E metastastic melanoma patients [3]. However,
due to the rapid acquisition of drug resistance caused by genetic
alterations, several additional targeted drugs were developed
against MAPK and PI3K/Akt pathways and now they are all used
in clinical trials [4,5]. While primary and acquired resistance are
still a problem to be fully understood, studies in preclinical models
suggested that combined approaches targeting multiple pathways
could be more effective than single-agent therapies for a durable
control of metastatic melanoma [6,7]. Recently, the first combined
clinical trial, using BRAF and MEK inhibitors on 162 BRAFV600
mutant melanoma patients, announced encouraging results for
progression-free survival improvements [8]. Therefore, a compre-
hensive knowledge of melanoma signalling pathways and mutation
patterns could suggest potential targets for novel personalized
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treatments and combinatorial strategies, to finally improve clinical
outcome of cutaneous malignant melanoma patients.
Systematic next-generation sequencing (NGS) approaches such
as whole-exome and whole-genome sequencing are powerful tools
for cancer mutation discovery providing an unbiased genome-wide
screening strategy and allowing the identification of potential
causative alterations in unexpected genes [9]. Whole-exome
sequencing (WES) enables to sequence all coding regions of the
human genome (namely, the exome) and is widely exploited in
cancer genomics, as recently implemented by The Cancer
Genome Atlas (TCGA) NIH project (http://cancergenome.nih.
gov/). Even though, with respect to whole-genome sequencing,
WES misses most intronic and regulatory regions, on the other
hand it allows to improve sequencing coverage and depth for
coding regions, thus providing high sensitivity to discover even
low-frequency mutations. So, for basic research and molecular
diagnostics applications, WES is currently the best NGS strategy
considering extensiveness, time and costs. In the last few years,
some WES investigations have been also performed on melanoma
cancers [10–14]. Overall, these studies evidenced that, having
already identified the most recurrent mutations typical of
melanoma, now the interest is for low-frequency mutations
(‘‘private’’ mutations), occurring in small groups of cases and
providing useful information to potentiate personalized medicine
approaches. Anyway, the major challenge remains the discrimi-
nation of the few ‘‘driver’’ mutations conferring a selective
advantage to tumor cells among the majority of ‘‘passenger’’
mutations with no causative role in cancer progression [14].
Cancer cell lines represent an in vitro model widely accepted to
study tumorigenic molecular processes. They have been used to
perform molecular and functional analyses useful to understand
the role of signalling pathways in cancer initiation and progression,
to discriminate potential driver from passenger mutations and to
identify novel candidate therapeutic targets [15]. Despite their
limitations to reflect human body complexity, tumor cell lines have
been also exploited in preclinical studies to screen potential
anticancer drugs. The research community agrees that systematic
drug screenings on well-characterized cancer cell lines will help to
identify genetic predictors of drug sensitivity, useful to assist patient
stratification for more personalized cancer treatments. To this
purpose, international cancer projects have currently created wide
collections of human cancer cell lines from different tumor types,
such as the NCI60 panel, the Cancer Cell Line Encyclopedia
(CCLE) [16] and the Sanger cell line panel [17], in order to
characterize their genetic background and test drug sensitivity,
resistance and toxicity.
Here, we provided an extensive genomic characterization for
coding mutations and DNA copy number alterations of six
melanoma cell lines derived from metastatic lesions of stage IIIc/
IV patients by WES and SNP array profiling. We catalogued
coding mutations with respect to Sanger COSMIC database and
to a manually curated list including genes involved in melanoma
pathways identified by querying recent literature. Besides
confirming known melanoma driver mutations, we identified
novel mutated genes involved in melanoma key signalling
cascades. We also identified novel genes never found mutated in
melanoma that might represent candidate targets to be further
investigated in larger datasets.
Results and Discussion
To extensively characterize the genetic background of our six
cutaneous malignant melanoma cell lines, we performed whole-
exome capture by Agilent SureSelect system and ultra-massive
sequencing by Illumina technology. Overall, we generated a mean
of 74 M raw reads per sample, of which more than 87%
successfully mapped to the NCBI human reference genome
GRCh37, thus resulting in a mean of 5 Gb of mapped sequences
per sample. After duplicate removal, 94.5% of captured target
regions were covered by at least one sequencing read (mean
coverage), while the mean on-target read depth was 45x (Table
S1).
By using GATK tool, we identified more than 128,000 single
nucleotide variants (SNVs) per sample, of which over 90% were
human known polymorphisms according to NCBI dbSNP132
database (including also Phase I 1000 Genomes Project variants)
(Table 1). Thus, we applied a series of progressively stringent
filtering steps to reduce this list to a sub-selection of novel and
highly confident variations in human coding regions (here termed
as HQ-SNVs) (Figure S1). To minimize the false positive rate, we
applied a stringent filter on the read depth at the single nucleotide
position to be called. In fact, by calculating SNP genotype call
concordance between SNP array and WES data in relation to
sequencing read depth, we obtained that concordance rate was
constantly high for homozygous positions (close to 100%
regardless of sequencing depth), while for heterozygous positions
it gradually increased as a function of read depth, reaching a 90%
plateau with at least 15 reads supporting the interrogated position
(Figure S2, Panel A). Thus, we set 15x as the minimum read depth
to call SNVs. All samples, but Me05, gave at least 80% on-target
coverage at 15x depth (Figure S2, Panel B). Finally, on the whole
dataset, we obtained a total of 3,325 novel coding HQ-SNVs,
including 1,153 synonymous and 2,172 non-synonymous (both
missense and nonsense) variants (Table 1). For each sample we
obtained a mean of 362 non-synonymous and 192 synonymous
HQ-SNVs. Me01 resulted by far the most mutated among the six
melanoma cell lines, while Me05 was the less mutated sample,
even if this can partly be due to its lower sequencing yields. Full
details for HQ-SNVs detected in each sample are available in our
Melanoma Exome Database (MExDB, at https://155.253.6.64/
MExDB/) and can be visualized in our GBrowse tool.
Overall, we calculated a ratio of non-synonymous to synony-
mous changes (NS/S) of 1.88:1 (range 1.62–2.16) (Table 1), which
was in range with the ratio predicted for non-selected passenger
mutations reported by other melanoma WES papers (between
2.0:1 and 1.9:1) [11,12]. According to the known melanoma
mutation signature associated with UV light exposure [18], the
Table 1. Single nucleotide variants (SNVs) summary.
Me01 Me02 Me04 Me05 Me08 Me12
Total SNVs
detected
128827 131830 159708 128087 161058 161721
Novel SNVs
detected
11126 8360 10230 6001 9534 7869
Novel coding
SNVs detected
2791 1626 1733 1117 1697 1224
Novel coding
HQ-SNVs
992 563 598 283 563 326
Non-synonymous
(NS)
659 385 370 189 369 200
Synonymous (S) 333 178 228 94 194 126
NS/S ratio 1.98 2.16 1.62 2.01 1.90 1.59
Abbreviations: SNVs, single nucleotide variants; HQ-SNVs, high-quality single
nucleotide variants.
doi:10.1371/journal.pone.0063597.t001
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analysis of nucleotide substitution pattern in all our six melanoma
cell lines confirmed that the C.T/G.A transition was the most
frequent mutation class (accounting for 45–69% of all substitu-
tions) (Figure 1).
To complete the genomic characterization of these melanoma
cell lines, we also assessed their DNA copy number alterations
(CNAs) by means of Affymetrix SNP array technology. The six
melanoma cell lines showed widely aberrant karyotypes, with large
amplifications and deletions involving even entire chromosomes
(Figure S3; CNA tracks are also provided by sample in our
GBrowse tool). In agreement with the typical melanoma genomic
signature, we found that the most recurrent CNAs included
amplifications on chrs 1 q, 6 p, 7, 8 q, 17 q and 20, and deletions
on chrs 6 q, 10 and 14 q [19].
To characterize our melanoma cell lines respecting already
known cancer genes, we compared our non-synonymous SNVs
with Sanger COSMIC mutations and our CNA results with the list
of COSMIC genes reported as deleted in cancer. Considering
overlap on exact genomic positions, we confirmed nine COSMIC
mutations (Table 2). The most frequent was the BRAFV600E
mutation occurring in four samples (66%), in a mutually exclusive
fashion with the NRASQ61R mutation, which we found in one (16%)
of the other two cell lines. Me05 was the only melanoma cell line
with both BRAF and NRAS wild-type genes. These are the two
oncogenes typically activated by mutation in malignant melano-
ma, reaching about 60% of cases for BRAF mutations (whose 80%
carries the pVal600Glu (V600E)) and 15–30% for NRAS
mutations [20]. Also, we found three other mutations already
reported in COSMIC for malignant melanoma (XKR6R162*,
MADDS1620F, PKHD1P1074S) and four mutations (in HYDIN,
SPTA1, SMC1B and MKS1) described in COSMIC for other
tumor types. Full details of characterization of these melanoma cell
lines for COSMIC cancer mutations are available in our MExDB.
Furthermore, we found 10 COSMIC deleted genes across five
melanoma cell lines (Table 2). Me05, with eight deleted genes,
resulted the most affected sample. Overall, CDKN2A resulted
affected by one- or two-copy losses in four samples (66%). Coding
for the cell cycle-regulator cyclin-dependent kinase inhibitor 2A, it
is the tumor suppressor gene (TSG) most frequently found totally
inactivated in up to 70% of melanomas by either homozygous
deletion or combination of mutation, one copy-deletion and
promoter methylation [19]. In addition, we found deletion of
several cancer genes reported in COSMIC for other tumor types,
such as MAP2K4 (described in ovary, lung and breast carcinomas),
APC (deleted in many different tumor kinds) and all those found in
Me05, namely AXIN1 (reported in stomach and liver adenocar-
cinomas), JAK2 and TET2 (hematopoietic neoplasms), KIT
(gastrointestinal stromal tumours and hematopoietic neoplasms),
PDGFRA (gastrointestinal stromal tumours), RB1 (brain and lung
cancers) and ZRANB1 (ovary carcinoma).
To characterize the individual genetic background of these cell
lines with regards to a more melanoma-focused gene panel, we
manually compiled an updated list of 547 melanoma-related genes
by combining already existing knowledge and recent literature
(File S1; see Methods for details) and we used it to search for
known and novel mutations. Then, to highlight particularly
impacted molecular processes, we grouped mutated genes
according to the signalling cascade or molecular function they
belong to. The most relevant classes are reported in Table 3.
Overall, Me01 resulted the most mutated sample with 28 mutated
genes, while Me12 presented the fewest mutations.
BRAF was the most frequently mutated gene and, together with
NRAS, they belong to the RAS-RAF Ser/Thr protein kinase
family. These two kinases play key roles in melanoma biology since
they are upstream activators of both the mitogen-activated protein
kinase (MAPK) and the phosphatidyl-inositol-3-phosphate kinase
(PI3K)/Akt signalling pathways, promoting uncontrolled tumor
growth and survival. The NS/S ratio calculated for this class
(5 non-synonymous to 0 synonymous variants) strongly confirmed
their driver role in melanoma genesis.
BRAF is also included in the MAPK signalling cascade, together
with MAP2K/MEK and MAPK/ERK proteins. Recently, two
WES papers investigated recurrent mutations in melanoma with a
specific focus on MAP3K [12] and MAP2K families [10]. In our
samples, we found 4 other mutated genes belonging to the MAPK
cascade, for which we calculated a global NS/S ratio of 2.7:1
(Table 3). Besides confirming MAP3K5 with a overall mutation
frequency (16%) consistent with that previously described (9–12%)
[12], we found a mutation in MAP3K4 (alias MEKK4 or MTK1),
for which loss-of-function mutations have been already reported in
5% of different tumors, but never in melanoma, suggesting a
potential tumor suppressive function as also proposed for MAP3K5
[12,21]. In addition, we found mutations inMAP2K3 (aliasMEK3),
a gene never previously reported mutated in COSMIC, but found
down-regulated in breast cancer with senescence-promoting
functions [22], and in MAPK6 (alias ERK3), occasionally reported
mutated in COSMIC for lung, breast and ovary adenocarcinomas
and skin squamous cell carcinoma, but never in melanoma, and
whose expression resulted strongly induced by BRAF and MEK in
melanoma [23]. Since Ras/Raf and MAPK are traditionally
targeted by kinase inhibitor drugs currently used in advanced
melanoma clinical trials, the knowledge about other potentially
Figure 1. Pattern of nucleotide substitutions. Novel coding single-nucleotide variants were divided and counted according to substitution class
in the six melanoma cell lines.
doi:10.1371/journal.pone.0063597.g001
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involved genes may be useful to suggest novel targets for
personalized treatments or combined strategies.
Concerning the PI3K/Akt pathway, we found 4 mutated genes
across four samples with a global NS/S ratio of 10:1 confirming
the driver role of this cascade in melanoma genesis (Table 3).
According to Berger et al. [13], we confirmed PREX2 as mutated
in two of our melanoma cell lines. Besides confirming one of the
mutations already described (the R463C), along with those
authors, we observed an atypical mutation pattern, with two and
three missense mutations in the same samples, distributed
throughout the entire gene length without a classical hot-spot.
This genetic feature has been already described for a class of non-
canonical oncogenes -such as ERBB4, FLT3 and EGFR- charac-
terized by multiple distributed mutations, each with independent
but synergistic effects [24,25]. Also, we found PIK3C2G affected in
two melanoma cell lines and double-mutated in one of them
(carrying a missense mutation together with a stop codon change).
This PI3-kinase gene has been proposed as potential oncogene
affected by genomic amplification in ovarian cancer cell lines [26].
Interestingly, another PIK3 gene, the PIK3CA, provides the
example of a widely studied oncogene of this pathway activated
by missense mutations in many tumor types and promoting cell
proliferation and invasion via Akt phosphorylation; also, in vitro
treatments with PIK3 inhibitors resulted in an effective tumor
growth arrest, so suggesting important implications for the
development of therapies targeting PIK3-mutated cancers [27].
Moreover, PI3K/Akt inhibitors have been tested in combination
with BRAF or MEK inhibitors in melanoma mouse models and
human cell lines and showed more promising results than mono-
specific targeted approaches [6,28].
The glutamate pathway is drastically involved in melanoma
biology and connected to MAPK and PI3K/Akt cascades. In our
dataset, we found 9 mutated genes belonging to this pathway
across three samples (Table 3). About ionotropic glutamate
receptors (iGluRs), instead of GRIN2A already reported for
melanoma [11], we found mutations in GRIN3A in two samples
and GRIN2B in one sample. These GRIN genes encode different
subunits of the N-methyl D-aspartate (NMDA) iGluRs, which
were seen critically involved in the regulation of epithelial-
mesenchymal transition in renal proximal tubular cells [29].
Especially, GRIN2B was proposed as TSG silenced by methylation
in several cancer types [30,31]. Also, treatment with NMDA
antagonists demonstrated to inhibit ERK1/2 pathway and reduce
tumor growth in lung adenocarcinoma and neuroblastoma mouse
models, suggesting the therapeutic potential of inhibiting gluta-
mate pathway for anticancer strategies [32]. About metabotropic
glutamate receptors (mGluRs), instead of GRM3 and GRM8
already described for melanoma [33], we found mutations in
GRM1 and GRM5 genes in two distinct samples and we confirmed
the involvement of their downstream signalling effector PLCB4,
according to previous reports [11], together with four other
phospholipase C genes. Both GRM1 and GRM5 resulted expressed
in melanoma cell lines and tissues and induced melanocyte
transformation and melanoma formation by ERK signalling
activation [34]. Interestingly, GRM1 and GRM5 showed to act
as independent oncogenes in melanoma mouse models [35].
Concerning their therapeutic potential for melanoma, pharmaco-
logical blockade by GRM1 antagonist or glutamate release
inhibitor demonstrated to drastically reduce tumor growth rate
[36]. Moreover, combined approaches targeting GRM1-mediated
glutamate release and multi-Raf kinases in melanoma cell lines
showed more promising results than single-agent therapies for a
durable control of metastatic disease [7]. Overall, our results
confirmed the importance of glutamate signalling in cutaneous
malignant melanoma.
Constitutive activation of tyrosine phosphorylation signalling
pathways is a classical hallmark of cancer resulting from both
activation of protein tyrosine kinase (PTKs) and inactivation of
protein tyrosine phosphatases (PTPs). According to Prickett et al.
[24], we found MET, PTK2B and PTK7 as mutated in three
distinct samples (Table 3). Furthermore, we found mutations in six
PTP genes across five of our melanoma cell lines. PTPRD was
mutated in one sample, with an overall frequency similar to that
previously reported (12%) [37]; in particular, this gene presented a
missense mutation together with complete deletion of the second
allele, as already described in melanoma and glioblastoma [37],
thus suggesting to be a potential key TSG. PTPN13 resulted
mutated in two samples and both PTPLA and PTPRF carried an
homozygous missense mutation in two distinct melanoma cell
lines. Recently, all these genes have been investigated as potential
TSGs because down-regulated in lung cancer cell lines; interest-
ingly, PTPN13 resulted the best candidate TSG since frequently
inactivated by deletion or mutation, acting as negative regulator of
EGFR and HER2 phosphorylation and activation [38]. In two
distinct samples, we found mutations in PTPRF and PTPRK, which
are involved in the regulation of epithelial contacts at adherens
junctions and whose inactivation showed to promote colon cancer
cell motility [39]. These studies suggest that these genes might play
Table 2. Confirmed COSMIC mutations and deletions.
COSMIC genes
Cell line Mutated Deleted
Me01 BRAF, HYDIN, SPTA1, XKR6* CDKN2A#
Me02 NRASD, SMC1B CDKN2A#, MAP2K4
Me04 BRAFD, MADD, SPTA1 2
Me05 MKS1 AXIN1, CDKN2A, JAK2, KIT, PDGFRA, RB1, TET2, ZRANB1
Me08 BRAF, PKHD1 APC, MAP2K4
Me12 BRAF CDKN2A#
In the column ‘‘mutated’’, we listed COSMIC genes for which we found mutation on the same genomic position as reported in COSMIC database (v58). In the column
‘‘deleted’’, we listed COSMIC genes for which we confirmed deletion spanning the entire gene locus. Genes recurrent in at least two samples are underlined.
*truncating mutation (stop codon);
Dhomozygous mutation (AF = 1);
#homozygous deletion (two-copy loss).
doi:10.1371/journal.pone.0063597.t002
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TSG functions also in melanoma pathology and may deserve
further investigations.
The metalloproteinase superfamily, including matrix metallo-
proteinases (MMP), a disintegrin and metalloproteinases (ADAM)
and ADAMs with thrombospondin domain (ADAMTS), are
proteolytic endopeptidase with several biological functions and
widely linked to cancer progression, metastasization and angio-
genesis [40]. Recently, they have been extensively screened for
coding mutations in melanoma [41,42]. In our dataset, we found 9
metalloproteinase genes mutated across four samples (Table 3).
Besides confirming ADAMTS18 and ADAMTS6 [42], we found
ADAMTS9 mutated in two samples and ADAMTS12 carrying an
heterozygous stop codon change in one sample. These two genes
have been reported silenced by hypermethylation in colon and
esophageal cancers [43,44]. Furthermore, ADAMTS12 showed
anti-tumorigenic protective functions by blocking ERK signalling
activation [45] and its absence in knockout mice resulted in
increased angiogenesis and tumor progression [46]. Concerning
the ADAM family, ADAM22 presented a missense mutation in one
sample together with complete deletion of the second allele, thus
suggesting a potential TSG function. This gene acts in brain as an
adhesion molecule inhibiting cell growth by integrin-dependent
interactions and was found down-regulated in high-grade gliomas
[47]. In addition, ADAM23, which we found affected in another
sample, was seen often silenced by hypermethylation in many
cancer types [48,49]. On the whole, for all these genes the findings
of our exome screening suggest a potential interest as novel
candidate melanoma TSGs and indicates the need for further
biological investigations.
The G protein-coupled receptors (GPCRs), comprising also the
aforementioned mGluRs, are the largest family of cell-surface
molecules responsible for regulation of several signalling pathways
in many different diseases. In cancer, specific GPCRs are involved
in aberrant growth, neo-angiogenesis and metastasis in different
tumors and huge efforts are now underway to exploit them and
their downstream effectors for development of novel therapeutic
strategies [50]. In our dataset, besides mGluRs, we found
mutations in 7 other GPCR genes across five samples (Table 3).
In addition to GPR112 reported mutated also by Prickett et al.
[33] and carrying a homozygous mutation in two of our samples,
we found GPR113 and GPR158 each mutated in two samples.
While GPR113 is a poorly studied gene and the only existing
reports are those in COSMIC for few stomach and ovary
adenocarcinoma cases, GPR158 has been already reported in
COSMIC for a wide range of primary tumors and one skin
malignant melanoma, and was found silenced by hypermethyla-
tion in esophageal squamous carcinoma cell lines [51]. Further-
more, one of our cell lines presented a homozygous truncating
mutation in GPR151. For this gene, COSMIC recorded two
missense mutations in pancreas and ovary tumors. Interestingly,
GPR151 (alias GALR4) encodes a galanin receptor and galanin
signalling has been found involved in several diseases and cancer,
offering interesting perspectives for receptor-targeting therapeutic
approaches [52]; linked to MAPK/ERK pathway, galanin
signalling showed to play distinct effects in different tumor types
[53,54]. These evidences supported a role for galanin in tumor
biology and proposed its receptors as potential targets for novel
therapeutic interventions with selective ligands or receptor
antagonists.
Besides the most represented classes here discussed, we also
found mutated genes belonging to other well-known molecular
processes (complete list in our MExDB). For example, Me01
presented a missense potentially deleterious mutation in the
BRCA2 gene, involved in DNA repair and genome integrity
maintenance and already reported mutated in melanoma [10]; this
might, at least partly, explain the high number of mutations we
exceptionally found in this cell line. Moreover, we found mutations
in two ligands (NRG1 and NRG3) of the tyrosine kinase EGF-
receptor ERBB4, which was recently proposed as novel mutated
oncogene for melanoma [24] and was seen involved in glutamate
signaling modulation [55], thus strengthening the importance to
have a global view of the pathway interactions active in melanoma
biology.
Additionally, using our curated melanoma-related list, we
characterized our cell lines for genes affected by two-copy losses
(or homozygous deletions, HD), an approach traditionally used to
identify TSGs completely inactivated in cancer cells. Besides the
classical HD of CDKN2A in three samples, including also the
neighboring CDKN2B in two of them, as previously reported [19],
we found HD affecting the G protein-receptor gene GPR21 and
the tyrosine kinase EPHA5 in two distinct cell lines. To our
knowledge, this is the first report for EPHA5 involvement in
melanoma, but Prickett et al. [24] already described mutations in
melanoma for other EPH genes. These genes belong to the ephrin
receptor family and contribute to glutamate signaling regulation
together with ERBB4 [56]. Moreover, we found other HDs, all in
Me12 sample, involving the MAP3K7 kinase, the ephrin receptor
EPHA7, the cyclin-dependent kinases CCNC and CDK19, and the
G protein-coupled receptors GPR45, GPR63, GPR6 and GRPC6A
(this latter already described mutated in melanoma [33]). These
results can be visualized by sample in the CN tracks of our
GBrowse tool.
Finally, to exploit the potentialities offered by a whole-exome
screening, we investigated the presence of mutations in those we
called ‘‘de novo’’ genes (i.e. genes not reported in COSMIC v58
nor included in our melanoma-related list). Focusing on multiple
occurrences, we found 10 genes mutated in at least two samples
(Table 4, full details in our MExDB). These genes showed
exclusively non-synonymous variations and some of them
presented peculiar mutations or position pattern. For instance,
PAICS showed the same missense mutation in two samples and in
homozygous status in one of them; MUC19 carried a different
truncating mutation in two samples, and in those same samples
MRPL1 presented the same codon affected by two different amino
acid changes; RBMXL1 resulted double-mutated and with the
same two missense mutations in two samples; ZNF66P was the
most recurrent gene mutated in three samples and with a different
stop codon change in two of them. By literature mining, we found
evidences linking four of these genes to tumorigenesis (see Table 4
for related literature).
MUC19 encodes a gel-forming mucin over-expressed in salivary
gland tumors, together with MUC1 and MUC4. Its transcription
increases in response to inflammatory cytokines and rare coding
variants have been recently associated with inflammatory bowel
diseases. This gene belongs to a wide family of glycoproteins
(mucins) now emerging as important molecules involved in cell
adhesion, polarity disruption and growth pathways activation in
inflammation and cancer, and already exploited as highly
attractive therapeutic targets for cancer vaccines, antibodies and
drug inhibitors [57]. The most prominent genes, MUC1 and
MUC4, showed aberrant expression in many tumors, directly
connected to invasive and metastatic properties. Little is known
about mucins in melanoma, where few papers reported the over-
expression of MUC4 with anti-apoptotic activity conferring
chemotherapy resistance. Interestingly, MUC4 is one of the novel
candidate melanoma genes recently identified by whole-genome
sequencing [13].
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PAICS, coding for a purine biosynthesis enzyme, was found
expressed in acute lymphoblastic leukemia; currently, this pathway
is targeted by many antileukemic agents [58]. In solid cancers,
PAICS was found over-expressed in lung squamous cell carcinoma,
probably reflecting the high proliferation rate of this tumor, and
showed a general association with glioblastoma progression-free
survival. Interestingly, by querying Oncomine database, we found
PAICS expression significantly up-regulated in melanoma versus
normal samples in Haqq melanoma dataset (p-value = 0.001;
https://www.oncomine.com/).
RBMXL1, encoding a RNA binding protein involved in splicing
process, was down-regulated by miR-421 in gastric cancer cells
and its reconstituted expression reduced tumor proliferation.
Accordingly, the expression of some RBMX genes was found
associated with that of pro-apoptotic genes in breast cancer, thus
supporting a tumor suppressive role for RBMXL1.
KIF23, alias MKLP1, encodes the mitotic kinesin-like protein 1
and participates to cytokinesis and chromosome segregation
during cell cycle. Its increased expression in many different cancer
types promoted tumor cell proliferation, suggesting its potential
interest as prognostic biomarker and therapeutic target. Recently,
another member of this gene family, the KIF20A, was proposed as
promising target for immunotherapy in advanced melanoma.
Taken as a whole, these evidences supported the involvement of
these four genes in cancer and suggested their potential interest
also for melanoma pathology, where further investigations in
larger datasets will be required.
Conclusions
Here, we performed a comprehensive genomic characterization
of six cutaneous malignant melanoma cell lines from metastatic
patients that represent precious research tools to better understand
melanoma pathways and their functional interplays. The melano-
ma cell lines here described presented chromosomal karyotypes
and mutational profiles well resembling those reported for primary
tumors. It is noteworthy that, although the small size of our sample
set, in these six melanoma cell lines we detected even some low-
frequency mutations only recently discovered in large panels of
melanoma tissues, such as PREX2 identified in 14% of a cohort of
107 metastatic melanomas [13]. We provide full details about
characterization of these melanoma cell lines in our MExDB and
GBrowse tool, as a publicly available resource for the entire
melanoma research community. We are currently planning to
expand the molecular characterization of these cells by RNA-seq
and promoter methylation analysis, as well as to perform
functional assays to ultimately validate the biological role of some
potentially interesting mutated genes we identified here. Such
results will be included in future works, with the final aim to
provide a full molecular characterization of these melanoma cell
lines. Although all cancer cell lines are a simplified model of
primary tumors and their major limitations remain the impossi-
bility to study the role of tumor microenvironment as well as the
pharmacokinetics effects exerted by human body on administered
drugs, we propose these six melanoma cell lines as useful tools for
basic research and preclinical applications. They may add useful
information for development of novel mutation-driven therapeutic
approaches and design of combined strategies targeting intercon-
nected pathways, an option which already promised to increase
success rate for melanoma therapy. Finally, the opportunity to test
drug sensitivity on well-characterized melanoma cells may help to
monitor the association between specific mutations and individual
drug resistance or toxicity, thus allowing to define alternative
treatments. These are the basis to achieve more accurate
personalized targeted therapies aimed to maximize treatment
efficacy while reducing side effects and resistance, to finally
Table 4. Recurrent de novo mutated genes.
Gene symbol
No. of mutated
samples (Sample
name)
No. of NS
mutations
GO Cellular
component
GO Biological
process Previous reports in cancer [PubMed ID]
C4orf23 2 (Me04,Me05) 2 cytoplasm tRNA processing
PAICS 2 (Me01,Me02) 2 cytoplasm purine metabolism ALL [PMID: 15142881], Lung squamous cell carcinoma [PMID:
15246564], Glioblastoma [PMID: 21649900]
CNST 2 (Me01,Me12) 2 plasma membrane Protein transport to
membrane
KIF23 2 (Me01,Me08) 2 nucleus cytokinesis Glioma [PMID: 21904957], Hepatocellular carcinoma [PMID:
21825042], NSCLC [PMID: 21412013], KIF20A in melanoma
[PMID: 22854760]
MRPL1 2 (Me01,Me08) 2 mitochondrion translation
MUC19 2 (Me01,Me08) 2 extracellular region cell adhesion Salivary gland tumors [PMID: 21072847], Inflammation [PMID:
19533339, 21983784], MUC1 and MUC4 in lung [PMID:
19318547], breast [PMID: 21277939], prostate [PMID: 16302265],
ovarian cancers [PMID: 20697346], melanoma [PMID: 19293191]
DCAKD 2 (Me01,Me04) 2 mitochondrion coenzyme A
biosynthetic process
MRPL53 2 (Me01,Me04) 2 mitochondrion translation
RBMXL1 2 (Me01,Me04) 4 nucleus RNA splicing Gastric cancer [PMID: 19802518], Breast cancer [PMID:
16552754]
ZNF66P 3 (Me01,Me04, Me05) 3 nucleus regulation of
transcription
Literature is indicated by PubMed ID code (PMID). References in italics concern other members of the same gene family involved in cancer and here reported to support
a potential interest for the listed mutated genes.
Abbreviations: NS, non-synonymous; GO, Gene Ontology; ALL, acute lymphoblastic leukemia; NSCLC, non-small cell lung cancer.
doi:10.1371/journal.pone.0063597.t004
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improve survival and quality of life of individuals affected by
cutaneous malignant melanoma.
Materials and Methods
Melanoma Cell Lines
Cancer cell lines were established in our laboratory from
surgical tissue samples of metastatic melanoma patients (Table S2),
after written informed consent, as described in Villablanca et al.
[59]. All research activities involving human subjects and derived
specimens were approved by the Institutional Ethics Committee of
Istituto Scientifico San Raffaele (Milan, Italy) and were conducted
according to the Declaration of Helsinki. For internal uses, the six
melanoma cell lines were labeled with a progressive number code
replacing their original sample names reported in Villablanca
et al. [59]: Me01 (CIP-5), Me02 (M3M005), Me04 (M3M001),
Me05 (MR245), Me08 (Ost) and Me12 (MR268). For additional
information see File S2.
Whole-genome Copy Number Alteration Analysis by
Affymetrix SNP Array
Genome-wide analysis of DNA copy number alterations (CNAs)
was performed using the GeneChipHHuman Mapping 250K SNP
Array platform (Affymetrix, Santa Clara, CA, USA) and Partek
Genomics Suite software (version 6.5; Partek Inc., St Louis, MO,
USA) (full details in File S2).
Whole-exome Capture and Sequencing
Exome capture was performed using the Agilent SureSelectXT
Human All Exon 50 Mb kit (Agilent Technologies, Santa Clara,
CA, USA). Ultra-massive sequencing was performed on the
Illumina GAIIx instrument, in a paired-end 76-cycle run. Illumina
SCS and CASAVA software were used for raw data processing
and fastq file generation.
Whole-exome Sequencing Data Analysis
Whole-exome sequencing (WES) paired-end reads were
mapped to the NCBI human reference genome GRCh37 build
using MAQ aligner (http://maq.sourceforge.net/). We focused
our attention on single nucleotide variants (SNVs), without
addressing further investigations to small insertions/deletions
(indels) or other possible structural variations. After duplicate
removal, GATK software was used for read quality score
recalibration, local realignment around indels and SNV calling.
Then, to create a sub-selection of novel coding high-quality SNVs
(HQ-SNVs) for further analyses, a series of filtering options was
applied, including minimum read depth of 15x, SNV call quality
score above 150 and non-reference allele frequency above 20%
(Figure S1). Moreover, SNVs already present in NCBI dbSNP132
(including also Phase I 1000 Genomes Project variants), located in
non-coding regions or mapping on HLA loci or homologous
repeated genes were filtered out, as well as SNVs overlapping to
variants already found in our in-house WES projects database. On
the basis of the ratio calculated by GATK between non-reference
and reference reads (termed ‘‘allele frequency’’ (AF)), SNVs were
classified as heterozygous (AF= 0.5) or homozygous (AF= 1)
variants. Finally, SIFT tool was used to predict potential protein-
function damage for non-synonymous missense HQ-SNVs
(http://sift.jcvi.org/). Complete details are available in File S2.
Concordance with SNP Array Genotype Calls
To assess reliability and sensitivity of our WES data for SNV
detection, genotype calls generated from WES and Affymetrix
SNP array for the six samples were compared and their
concordance was evaluated in relation to sequencing read depth
(see File S2 for complete description). From this analysis we
defined the minimum read depth for SNV calling.
Bioinformatics Analysis
COSMIC gene list. SNV and CNA data were compared
with Sanger Catalogue Of Somatic Mutations In Cancer
(COSMIC database v58, ftp://ftp.sanger.ac.uk/pub/CGP/
cosmic/). Mutation and deletion overlaps were evaluated in order
to characterize our samples respecting already known cancer
genes.
Manually curated list of melanoma-related genes. We
manually compiled a comprehensive and updated list of melano-
ma-related genes by combining genes already known according to
traditional knowledge and those proposed as novel candidate
genes by recently published literature and extending the list so to
include all the members belonging to those given gene families.
The final list comprised 30 gene families from the canonical
KEGG Melanoma pathway (map05218) and other 26 gene
families derived from recent melanoma WES or targeted
sequencing papers [10–13,24,33,37,41,42,60], for a total of 547
potentially melanoma-related genes (File S1). This list was used to
extensively screen our melanoma cell lines for known and novel
mutations; then, to highlight particularly impacted molecular
processes, mutated genes were grouped according to the signaling
cascade or molecular function they belong to.
Web Resources
All the HQ-SNVs found in each melanoma cell line were
collected into our SQLite-based Melanoma Exome Database
(MExDB), publicly available at https://155.253.6.64/MExDB/.
Moreover, a GBrowse genome viewer is available at http://155.
253.6.64/cgi-bin/gb2/gbrowse/melanoma_exome_agilent/to
browse throughout chromosomes and samples, for visualizing read
alignments, SNV positions and read depth and Partek CNA
regions.
Supporting Information
Figure S1 Flowchart of WES data analysis pipeline. The
flowchart illustrates the analytical steps carried out to process and
analyze WES data, from reads alignment to single nucleotide
variant (SNV) calling by GATK and subsequent filtering to obtain
a sub-selection of high-quality SNVs (HQ-SNVs). To store,
manage and share data produced, a public database (Melanoma
Exome Database, MExDB) and a GBrowse genome viewer tool
were implemented as freely available resources for the entire
research community.
(PDF)
Figure S2 Genotype call concordance between WES and
SNP array data and on-target coverage by sequencing
read depth. In Panel A, SNP call concordance between WES
and SNP array data on the whole cell line panel was calculated in
relation to sequencing read depth and separately plotted for
homozygous reference (AF=0, blue line), homozygous non-
reference (AF= 1, green line) and heterozygous variations
(AF= 0.5, red line). Finally, we chose to set at 15x the minimum
read depth for SNV calling. In Panel B, for each melanoma cell
line, mean coverage on captured target regions was plotted in
relation to sequencing read depth. At 15x depth threshold, all
samples but Me05 gave at least 80% on-target coverage.
(PNG)
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Figure S3 Whole-genome copy number alteration (CNA)
profiles of the six cutaneous malignant melanoma cell
lines. Analysis was performed using Partek Genomics Suite (v6.5)
and comparing each melanoma cell line to a normal reference
pool. Along each chromosome (from 1 to 22), copy number
alteration (CNA) regions are reported by sample (samples are
ordered from left to right, from Me01 to Me12). Color code is used
to distinguish amplifications (red tracks, for regions with CN value
above 2.3) and deletions (blue tracks, for regions with CN value
less than 1.3, including both one-copy and two-copy losses). All
these CNA regions can be visualized in detail in our GBrowse tool.
(JPEG)
Table S1 Whole-exome sequencing (WES) results.
(PDF)
Table S2 Characteristics of cutaneous malignant mel-
anoma patients and derived cell lines.
(PDF)
File S1 List of melanoma-related genes and gene
families. A comprehensive and updated list of melanoma-related
genes was created by combining genes and gene families derived
from canonical KEGG Melanoma Pathway (map05218) to those
proposed by recent melanoma WES or targeted sequencing papers
(see File S2 for literature). Finally, the list comprised 56
melanoma-related gene families, for a total of 547 genes. Gene
families were grouped according to signalling cascade or molecular
function they belong to, in order to have a functional view of
mutated genes and highlight particularly impacted molecular
processes.
(XLS)
File S2 Supplementary methods (extended version).
(PDF)
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